CD38high/HLA-DR+CD8+ T lymphocytes display pathogen-specific expansion regardless of hemophagocytic lymphohistiocytosis
- PMID: 39226525
- DOI: 10.1002/eji.202451140
CD38high/HLA-DR+CD8+ T lymphocytes display pathogen-specific expansion regardless of hemophagocytic lymphohistiocytosis
Abstract
The characteristic expansion of T CD38high/HLA-DR+CD8+ lymphocytes observed in hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) proved able to distinguish HLH/MAS from sepsis and systemic juvenile idiopathic arthritis. However, the performance of this marker in differentiating HLH/MAS from other pediatric febrile conditions with similar clinical onset and yet entirely different treatments remains unexplored. CD38high/HLA-DR+CD8+ frequencies measured in the peripheral fresh blood of pediatric patients attended for suspicion of HLH/MAS were retrospectively recorded and clinical characteristics were retrieved. CD38high/HLA-DR+CD8+ frequencies in HLH/MAS patients (15 patients; median: 22.0%, IQR: 11.0-49.0%) were compared with those who presented febrile conditions other-than-HLH (28 patients; median: 13.0%, IQR: 3.9-28.7%; p = 0.24). HLH and non-HLH patients were subsequently regrouped based on the presence of an identified infection (22 patients; median: 27.0%, IQR: 15.2-72.1%) and compared with those without infections (21 patients; median: 7.6%, IQR: 3.7-24.3%; p = 0.0035). CD38high/HLA-DR+CD8+ percentages were significantly higher only in the infection group compared with the noninfection one, with a patent pathogen-specific expansion in Epstein-Barr virus primoinfection and visceral leishmaniasis regardless of the presence of HLH. CD38high/HLA-DR+CD8+ frequencies do not appear as an HLH-specific marker as they naturally expand in other clinical situations that are common in childhood and may mimic HLH initial presentation.
Keywords: CD38high/HLA‐DR+CD8+ lymphocytes; Hemophagocytic lymphohistiocytosis; Macrophage activation syndrome.
© 2024 The Author(s). European Journal of Immunology published by Wiley‐VCH GmbH.
References
-
- La Rosée, P., Horne, A., Hines, M., von Bahr Greenwood, T., Machowicz, R., Berliner, N., Birndt, S. et al., Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019. 133: 2465–2477.
-
- Zinter, M. S. and Hermiston, M. L., Calming the storm in HLH. Blood. 2019. 134: 103–104.
-
- Bracaglia, C., Prencipe, G. M. S. and De Benedetti, F., Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome. Pediatr. Rheumatol. Online J. 2017. 15: 5.
-
- Henter, J. I., Horne, A. C., Aricó, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S. et al., HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood. Cancer. 2007. 48: 124–131.
-
- Ravelli, A., Minoia, F., Davì, S., Horne, A., Bovis, F., Pistorio, A., Aricò, M. et al., 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016. 68: 566–576.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
